ppar alpha

Summary

Summary: A nuclear transcription factor. Heterodimerization with RETINOID X RECEPTOR GAMMA is important to metabolism of LIPIDS. It is the target of FIBRATES to control HYPERLIPIDEMIA.

Top Publications

  1. ncbi Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states
    Michael K Badman
    Division of Endocrinology, Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Cell Metab 5:426-37. 2007
  2. ncbi Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21
    Takeshi Inagaki
    Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Cell Metab 5:415-25. 2007
  3. pmc Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation
    Aparna Purushotham
    Laboratory of Signal Transduction, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA
    Cell Metab 9:327-38. 2009
  4. pmc Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis
    Philippe Lefebvre
    Departement d Atherosclerose, Institut Pasteur de Lille, INSERM U545, and Université de Lille 2, Lille, France
    J Clin Invest 116:571-80. 2006
  5. pmc Feeding pregnant rats a protein-restricted diet persistently alters the methylation of specific cytosines in the hepatic PPAR alpha promoter of the offspring
    Karen A Lillycrop
    Development and Cell Biology, Biomedical Sciences Building, University of Southampton, Bassett Crescent East, Southampton SO16 7PX, UK
    Br J Nutr 100:278-82. 2008
  6. pmc Identification of a physiologically relevant endogenous ligand for PPARalpha in liver
    Manu V Chakravarthy
    Endocrinology, Metabolism, and Lipid Research, Department of Medicine, Washington University School of Medicine, Campus Box 8127, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Cell 138:476-88. 2009
  7. ncbi Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids
    Yuriko Adkins
    Western Human Nutrition Research Center, ARS, USDA, University of California Davis, CA 95616, USA
    J Nutr Biochem 21:781-92. 2010
  8. ncbi Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity
    Rinke Stienstra
    Nutrigenomics Consortium, TI Food and Nutrition, Wageningen, The Netherlands
    Hepatology 51:511-22. 2010
  9. pmc Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation
    Carlos Solorzano
    Department of Pharmacology, University of California, Irvine, CA 92697 4624, USA
    Proc Natl Acad Sci U S A 106:20966-71. 2009
  10. ncbi MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin-resistant human colon cancer cells
    Jin Lu Tong
    Division of Gastroenterology and Hepatology, Shanghai Jiao Tong University School of Medicine, Renji Hospital, Shanghai, China
    FEBS Lett 585:3560-8. 2011

Detail Information

Publications292 found, 100 shown here

  1. ncbi Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states
    Michael K Badman
    Division of Endocrinology, Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Cell Metab 5:426-37. 2007
    ..These findings identify hepatic FGF21 as a critical regulator of lipid homeostasis and identify a physiological role for this hepatic hormone...
  2. ncbi Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21
    Takeshi Inagaki
    Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Cell Metab 5:415-25. 2007
    ..These findings demonstrate an unexpected role for the PPARalpha-FGF21 endocrine signaling pathway in regulating diverse metabolic and behavioral aspects of the adaptive response to starvation...
  3. pmc Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation
    Aparna Purushotham
    Laboratory of Signal Transduction, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA
    Cell Metab 9:327-38. 2009
    ..Taken together, our data indicate that SIRT1 plays a vital role in the regulation of hepatic lipid homeostasis and that pharmacological activation of SIRT1 may be important for the prevention of obesity-associated metabolic diseases...
  4. pmc Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis
    Philippe Lefebvre
    Departement d Atherosclerose, Institut Pasteur de Lille, INSERM U545, and Université de Lille 2, Lille, France
    J Clin Invest 116:571-80. 2006
    ..This Review will focus on the mechanisms of action of PPARalpha in metabolic diseases and their associated vascular pathologies...
  5. pmc Feeding pregnant rats a protein-restricted diet persistently alters the methylation of specific cytosines in the hepatic PPAR alpha promoter of the offspring
    Karen A Lillycrop
    Development and Cell Biology, Biomedical Sciences Building, University of Southampton, Bassett Crescent East, Southampton SO16 7PX, UK
    Br J Nutr 100:278-82. 2008
    ..PR) diet with different amounts of folic acid on the methylation of individual CpG dinucleotides in the hepatic PPAR alpha promoter in juvenile offspring, and the effect of the maternal PR diet on CpG methylation in adult offspring...
  6. pmc Identification of a physiologically relevant endogenous ligand for PPARalpha in liver
    Manu V Chakravarthy
    Endocrinology, Metabolism, and Lipid Research, Department of Medicine, Washington University School of Medicine, Campus Box 8127, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Cell 138:476-88. 2009
    ..Portal vein infusion of 16:0/18:1-GPC induced PPARalpha-dependent gene expression and decreased hepatic steatosis. These data suggest that 16:0/18:1-GPC is a physiologically relevant endogenous PPARalpha ligand...
  7. ncbi Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids
    Yuriko Adkins
    Western Human Nutrition Research Center, ARS, USDA, University of California Davis, CA 95616, USA
    J Nutr Biochem 21:781-92. 2010
    ..This review examines the various mechanisms by which n-3 PUFA exert beneficial effects against CVD...
  8. ncbi Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity
    Rinke Stienstra
    Nutrigenomics Consortium, TI Food and Nutrition, Wageningen, The Netherlands
    Hepatology 51:511-22. 2010
    ..Finally, IL-1beta and NF-kappaB interfered with the ability of PPARalpha to activate gene transcription...
  9. pmc Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation
    Carlos Solorzano
    Department of Pharmacology, University of California, Irvine, CA 92697 4624, USA
    Proc Natl Acad Sci U S A 106:20966-71. 2009
    ..The PEA-hydrolyzing amidase NAAA may provide a previously undescribed target for antiinflammatory medicines...
  10. ncbi MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin-resistant human colon cancer cells
    Jin Lu Tong
    Division of Gastroenterology and Hepatology, Shanghai Jiao Tong University School of Medicine, Renji Hospital, Shanghai, China
    FEBS Lett 585:3560-8. 2011
    ....
  11. ncbi Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination
    Atsushi Tsuchida
    Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Diabetes 54:3358-70. 2005
    ....
  12. ncbi Effects of the peroxisome proliferator-activated receptor-alpha agonists clofibrate and fish oil on hepatic fatty acid metabolism in weaned dairy calves
    N B Litherland
    Department of Animal Sciences, University of Illinois, Urbana 61801, USA
    J Dairy Sci 93:2404-18. 2010
    ..Applications of PPARalpha agonists may be of interest to increase the rate of hepatic fatty acid oxidation and decrease triacylglycerol accumulation in periparturient dairy cows...
  13. pmc Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors
    Miriam Melis
    B B Brodie Department of Neuroscience, University of Cagliari, 09042 Monserrato, Italy
    J Neurosci 28:13985-94. 2008
    ..These data indicate for the first time that the anorexic lipids OEA and PEA possess neuromodulatory properties as endogenous ligands of PPAR-alpha in the brain and provide a potential new target for the treatment of nicotine addiction...
  14. pmc The G0/G1 switch gene 2 is a novel PPAR target gene
    Fokko Zandbergen
    Nutrition, Metabolism and Genomics Group, Wageningen University, 6700 EV, Wageningen, The Netherlands
    Biochem J 392:313-24. 2005
    ..Together, these data indicate that G0S2 is a novel target gene of PPARs that may be involved in adipocyte differentiation...
  15. ncbi PPAR-alpha activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-Kinase/Akt and NO pathway
    Aliaksandr A Bulhak
    Division of Cardiology, Department of Medicine, The Rolf Luft Center for Diabetes Research, Karolinska University Hospital, Solna, S 171 76 Stockholm, Sweden
    Am J Physiol Heart Circ Physiol 296:H719-27. 2009
    ..05). The results suggest that PPAR-alpha activation protects the type 2 diabetic rat myocardium against ischemia-reperfusion injury via the activation of the PI3K/Akt and NO pathway...
  16. ncbi The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man
    Cecilia Gälman
    Department of Endocrinology, Metabolism and Diabetes, Molecular Nutrition Unit, Karolinska Institutet, Karolinska University Hospital Huddinge, S 141 86 Stockholm, Sweden
    Cell Metab 8:169-74. 2008
    ..The wide interindividual variation and the induction of ketogenesis independent of FGF21 levels indicate that the physiological role of FGF21 in humans may differ from that in mice...
  17. ncbi A potential link between muscle peroxisome proliferator- activated receptor-alpha signaling and obesity-related diabetes
    Brian N Finck
    Center for Cardiovascular Research, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Cell Metab 1:133-44. 2005
    ..These results identify PPARalpha-driven alterations in muscle fatty acid oxidation and energetics as a potential link between obesity and the development of glucose intolerance and insulin resistance...
  18. ncbi Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-alpha) in the development of inflammatory bowel disease in mice
    Salvatore Cuzzocrea
    Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, University of Messina, Policlinico Universitario, Messina, Italy
    Lab Invest 84:1643-54. 2004
    ..Thus, endogenous and exogenous PPAR-alpha ligands reduce the degree of colitis caused by DNBS. We propose that PPAR-alpha ligand may be useful in the treatment of inflammatory bowel disease...
  19. ncbi Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease
    Jean Charles Fruchart
    Laboratoire J and K, INSERM UR 545, Universite Lille 2, Faculte de Medecine de Lille, Pole Recherche, Lille Cedex, France
    Atherosclerosis 205:1-8. 2009
    ..It is anticipated that PPARalpha will continue to have important clinical application in addressing the major challenge of cardiometabolic risk associated with type 2 diabetes, obesity and metabolic syndrome...
  20. pmc Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism
    Bertrand Cariou
    Department of Endocrinology, l institut du thorax, Nantes University Hospital, Nantes, France
    Diabetes Care 34:2008-14. 2011
    ..We evaluated the metabolic effects and tolerability of GFT505, a novel dual peroxisome proliferator-activated receptor α/δ agonist, in abdominally obese patients with either combined dyslipidemia or prediabetes...
  21. ncbi The role of PPARalpha in lipid metabolism and obesity: focusing on the effects of estrogen on PPARalpha actions
    Michung Yoon
    Department of Life Sciences, Mokwon University, Taejon 302 729, Republic of Korea
    Pharmacol Res 60:151-9. 2009
    ..Thus, the use of fibrates seems to be effective in men and postmenopausal women with obesity and lipid disorders, but not in premenopausal women with functioning ovaries...
  22. ncbi n-3 Fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator-activated receptor-alpha-dependent manner
    Susanne Neschen
    Yale University School of Medicine, Howard Hughes Medical Institute, Departments of Internal Medicine, The Anlyan Center, P O Box 9812, New Haven, CT 06536 8012, USA
    Diabetes 56:1034-41. 2007
    ..0001 vs. genotype control). These data support the hypothesis that n-3 fatty acids protect from high-fat diet-induced hepatic insulin resistance in a PPAR-alpha-and diacylglycerol-dependent manner...
  23. ncbi Palmitoylethanolamide protects dentate gyrus granule cells via peroxisome proliferator-activated receptor-α
    Marco Koch
    Dr Senckenbergische Anatomie, Institut für Anatomie II, Goethe Universitat, Frankfurt am Main, Germany
    Neurotox Res 19:330-40. 2011
    ..In addition to classical endocannabinoids, PEA-mediated PPAR-alpha activation represents a possible target for therapeutic interventions to mitigate symptoms of secondary neuronal damage...
  24. ncbi Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes
    Robert E Ratner
    MedStar Research Institute, Hyattsville, MD 20783, USA
    Diab Vasc Dis Res 4:214-21. 2007
    ..The clinical development of tesaglitazar is no longer continuing; its effects on the glucose and lipid abnormalities of type 2 diabetes suggest that the concept of dual PPARalpha/gamma agonism is worthy of further investigation...
  25. ncbi Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver
    Yuichi Harano
    Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
    Liver Int 26:613-20. 2006
    ..Peroxisome proliferator-activated receptor (PPAR) alpha controls fatty acid metabolism. In the present study, we investigated the effect of fenofibrate, a PPARalpha agonist, on hepatic steatosis in FLS mice...
  26. ncbi Peroxisome proliferator-activated receptor alpha interacts with high affinity and is conformationally responsive to endogenous ligands
    Heather A Hostetler
    Department of Physiology and Pharmacology, Texas A and M University, TVMC, College Station, Texas 77843 4466, USA
    J Biol Chem 280:18667-82. 2005
    Although the peroxisome proliferator-activated receptor (PPAR alpha) binds and is activated by a variety of synthetic xenobiotics, the identity of the high affinity endogenous ligand(s) is incompletely resolved...
  27. ncbi Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats
    Jin Fu
    Department of Psychiatry, University of California, Irvine, CA 92697 4625, USA
    Neuropharmacology 48:1147-53. 2005
    ..The results suggest that OEA regulates lipid metabolism and that this effect may contribute to its anti-obesity properties...
  28. ncbi Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation
    Atsuko Tomizawa
    Department of Endocrinology and Metabolism, Dokkyo University School of Medicine, Mibu, Tochigi 321 0293, Japan
    Metabolism 60:513-22. 2011
    ..Our findings suggest that fenofibrate might exert a protective effect on the microvasculature by suppressing inflammation and apoptosis through AMPK activation beyond its lipid-lowering actions...
  29. pmc Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome
    Renata Belfort
    The University of Texas Health Science Center at San Antonio, Diabetes Division, Room 3 380S, 7703 Floyd Curl Drive, San Antonio, Texas 78284 3900, USA
    J Clin Endocrinol Metab 95:829-36. 2010
    ..Fenofibrate is a peroxisome proliferator-activated receptor alpha agonist widely used in clinical practice, but its mechanism of action is incompletely understood...
  30. ncbi Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha
    Myeong Jin Yoon
    Department of Biological Sciences, Seoul National University, Gwanak Gu, Seoul 151 742, Korea
    Diabetes 55:2562-70. 2006
    ..Taken together, these results suggest that adiponectin stimulates fatty acid oxidation in muscle cells by the sequential activation of AMPK, p38 MAPK, and PPARalpha...
  31. ncbi Activation of mouse and human peroxisome proliferator-activated receptors (alpha, beta/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate
    Margy L Takacs
    Reproductive Toxicology Division, National Health and Environmental Effects Research Laboratory, Office of Research and Development, US Environmental Protection Agency, Research Triangle Park, North Carolina 27711, USA
    Toxicol Sci 95:108-17. 2007
    ....
  32. ncbi Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer
    Yoshihito Yokoyama
    Department of Obstetrics and Gynecology, Hirosaki University School of Medicine, Hirosaki, Amori, Japan
    Mol Cancer Ther 6:1379-86. 2007
    ..We conclude that CA could be an effective agent in ovarian cancer and should be tested alone and in combination with other anticancer drugs...
  33. ncbi Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway
    Jaetaek Kim
    Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Chung Ang University, 224 1 Heuk Seok dong, Dongjak Ku, Seoul 156 755, South Korea
    Exp Eye Res 84:886-93. 2007
    ..Thus fenofibrate may have a novel therapeutic property that can control unwanted cell death found in diabetic retinopathy...
  34. ncbi The search for the palmitoylethanolamide receptor
    Jesse LoVerme
    Center for Drug Discovery, University of California, Irvine, CA 92697 4260, USA
    Life Sci 77:1685-98. 2005
    ..Here we outline the history of PEA, starting with its initial discovery in the 1950s, and discuss the pharmacological properties of this compound, particularly in regards to its ability to activate PPAR-alpha...
  35. ncbi Peroxisomal proliferation protects from beta-amyloid neurodegeneration
    Manuel J Santos
    Unidad de Bioquímica Celular y Genética, Facultad de Ciencias Biologicas, Pontificia Universidad Catolica de Chile, Casilla 114 D, Santiago, Chile
    J Biol Chem 280:41057-68. 2005
    ..Our data suggest, for the first time, a direct link between peroxisomal proliferation and neuroprotection from Abeta-induced degenerative changes...
  36. ncbi Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice
    A Susanne M Zadelaar
    Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands
    Arterioscler Thromb Vasc Biol 26:2560-6. 2006
    ..We investigated whether the dual PPARalpha/gamma agonist tesaglitazar has anti-atherogenic effects in ApoE*3Leiden mice with reduced insulin sensitivity...
  37. ncbi Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker rats
    Nicholas D Oakes
    AstraZeneca R and D Molndal, S 431 83 Molndal, Sweden
    Am J Physiol Regul Integr Comp Physiol 289:R938-46. 2005
    ..The present work demonstrates that tesaglitazar ameliorates these abnormalities and enhances insulin sensitivity in this animal model...
  38. pmc Gene expression of transporters and phase I/II metabolic enzymes in murine small intestine during fasting
    Heleen M van den Bosch
    Nutrition, Metabolism and Genomics Group, Division of Human Nutrition, Wageningen, University, Wageningen, The Netherlands
    BMC Genomics 8:267. 2007
    ..We therefore investigated the effects of fasting on expression of these genes using Affymetrix GeneChip MOE430A arrays and quantitative RT-PCR...
  39. ncbi Profiling of gene expression in rat liver and rat primary cultured hepatocytes treated with peroxisome proliferators
    Kotaro Tamura
    Toxicogenomics Project, National Institute of Biomedical Innovation, Ibaraki, Osaka, Japan
    J Toxicol Sci 31:471-90. 2006
    ....
  40. ncbi Acetic acid upregulates the expression of genes for fatty acid oxidation enzymes in liver to suppress body fat accumulation
    Tomoo Kondo
    Central Research Institute, Mizkan Group Corporation, Handa, Aichi 475 8585, Japan
    J Agric Food Chem 57:5982-6. 2009
    ..In conclusion, AcOH suppresses accumulation of body fat and liver lipids by upregulation of genes for PPARalpha and fatty-acid-oxidation-related proteins by alpha2 AMPK mediation in the liver...
  41. ncbi Fenofibrate lowers lipid accumulation in myotubes by modulating the PPARα/AMPK/FoxO1/ATGL pathway
    Wei Lu Chen
    Graduate Institute of Medical Sciences, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan
    Biochem Pharmacol 84:522-31. 2012
    ..Taken together, our results suggest that the lipid-lowering effect of fenofibrate was achieved by activating PPARα and AMPK signaling pathway that resulted in increasing ATGL expression, lipolysis, and fatty acid β-oxidation...
  42. pmc Anti-obesity efficacy of LH-21, a cannabinoid CB(1) receptor antagonist with poor brain penetration, in diet-induced obese rats
    Monica Alonso
    Laboratorio de Medicina Regenerativa, Hospital Regional Universitario Carlos Haya, Fundacion IMABIS, Malaga, Spain
    Br J Pharmacol 165:2274-91. 2012
    ..In this study we analysed the effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist with poor brain penetration, in an animal model of diet-induced obesity...
  43. pmc Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in human hepatocytes
    Alexandra Rogue
    UMR INSERM U991, Faculte des Sciences Pharmaceutiques et Biologiques, Rennes, France
    PLoS ONE 6:e18816. 2011
    ..Since the liver plays a key role in lipid metabolism, we analyzed changes in gene expression profiles induced by these two types of PPAR agonists in human hepatocytes...
  44. ncbi Fenofibrate and metabolic syndrome
    Aldi T Kraja
    Division of Statistical Genomics, Washington University School of Medicine, 4444 Forest Park Ave, Campus Box 8506, St Louis, MO 63110, USA
    Endocr Metab Immune Disord Drug Targets 10:138-48. 2010
    ..However, more work is needed to specifically identify which individuals derive a benefit from FF administration in terms of clinical outcomes and which do not - particularly in the context of type 2 diabetes...
  45. pmc Palmitoylation of ketogenic enzyme HMGCS2 enhances its interaction with PPARalpha and transcription at the Hmgcs2 PPRE
    Morris A Kostiuk
    Department of Cell Biology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
    FASEB J 24:1914-24. 2010
    ....
  46. ncbi Natural compounds regulate energy metabolism by the modulating the activity of lipid-sensing nuclear receptors
    Tsuyoshi Goto
    Laboratory of Molecular Function of Food, Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Uji 611 0011, Japan
    Mol Nutr Food Res 57:20-33. 2013
    ....
  47. pmc Hepatocyte nuclear factor 4alpha coordinates a transcription factor network regulating hepatic fatty acid metabolism
    Celia Pilar Martinez-Jimenez
    Biomedical Sciences Research Center Alexander Fleming, 16672 Vari, Greece
    Mol Cell Biol 30:565-77. 2010
    ..These results establish the fundamental role of dynamic regulatory interactions between HNF4alpha, Hes6, PPARalpha, and PPARgamma in the coordinated expression of genes involved in fatty acid transport and metabolism...
  48. pmc Fenofibrate simultaneously induces hepatic fatty acid oxidation, synthesis, and elongation in mice
    Maaike H Oosterveer
    Department of Pediatrics, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands
    J Biol Chem 284:34036-44. 2009
    ..These observations may reflect a physiological mechanism by which PPARalpha and SREBP-1c collectively ensure proper handling of fatty acids to protect the liver against cytotoxic damage...
  49. pmc Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human
    Maryam Rakhshandehroo
    Nutrigenomics Consortium, Top Institute TI Food and Nutrition, Wageningen, The Netherlands
    PLoS ONE 4:e6796. 2009
    ..However, little information is available on the role of PPARalpha in human liver. Here we set out to compare the function of PPARalpha in mouse and human hepatocytes via analysis of target gene regulation...
  50. pmc The glucagon receptor is required for the adaptive metabolic response to fasting
    Christine Longuet
    Department of Medicine, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario M5G 1X5, Canada
    Cell Metab 8:359-71. 2008
    ..The actions of glucagon on TG synthesis and FAO were abolished in PPARalpha-/- hepatocytes. These findings demonstrate that the Gcgr receptor is required for control of lipid metabolism during the adaptive metabolic response to fasting...
  51. pmc Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-activated receptors PPARalpha and PPARdelta
    Pascal J H Smeets
    Department of Physiology, Cardiovascular Research Institute Maastricht, Maastricht University, 6200 MD Maastricht, The Netherlands
    J Biol Chem 283:29109-18. 2008
    ..It was shown that both PPARalpha and PPARdelta are able to mitigate cardiomyocyte hypertrophy in vitro by inhibiting NF-kappaB activation...
  52. ncbi Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk
    Lisa M Younk
    University of Maryland School of Medicine, Department of Medicine, Baltimore, MD 21201, USA
    Expert Opin Drug Metab Toxicol 7:753-63. 2011
    ....
  53. pmc PPARalpha-mediated effects of dietary lipids on intestinal barrier gene expression
    Heleen M de Vogel-van den Bosch
    Nutrition, Metabolism and Genomics Group, Division of Human Nutrition, Wageningen University, PO Box 8129, NL 6700EV, Wageningen, The Netherlands
    BMC Genomics 9:231. 2008
    ..To this end we used triacylglycerols composed of identical fatty acids in combination with gene expression profiling in wild-type and PPARalpha-null mice. Treatment with the synthetic PPARalpha agonist WY14643 served as reference...
  54. pmc N-3 polyunsaturated fatty acid regulation of hepatic gene transcription
    Donald B Jump
    Department of Nutrition and Exercise Sciences, Linus Pauling Institute, Oregon State University, Corvallis, Oregon 97331 5109, USA
    Curr Opin Lipidol 19:242-7. 2008
    ..This review brings together metabolic and molecular studies that help explain n-3 (omega-3) polyunsaturated fatty acid regulation of hepatic gene transcription...
  55. ncbi PPAR alpha mediates transcriptional upregulation of novel organic cation transporters-2 and -3 and enzymes involved in hepatic carnitine synthesis
    Alexander Koch
    Institute of Agricultural and Nutritional Sciences, Martin Luther University Halle Wittenberg, D 06108 Halle Saale, Germany
    Exp Biol Med (Maywood) 233:356-65. 2008
    ..Therefore, wild-type mice and mice deficient in PPAR alpha (PPAR alpha-/-) were treated with the PPAR alpha agonist WY 14,643...
  56. pmc Modulation of peroxisome proliferator-activated receptor-alpha activity by N-acetyl cysteine attenuates inhibition of oligodendrocyte development in lipopolysaccharide stimulated mixed glial cultures
    Manjeet K Paintlia
    Department of Pediatrics, Medical University of South Carolina and Ralph H Johnson VA Medical Center, Charleston, South Carolina 29425, USA
    J Neurochem 105:956-70. 2008
    ....
  57. ncbi PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes
    Yeon Seok Seo
    Department of Internal Medicine, Korea University College of Medicine, Guro Hospital, Seoul, Korea
    J Gastroenterol Hepatol 23:102-9. 2008
    ....
  58. pmc Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects
    Robert S Rosenson
    Department of Cardiometabolic Disorders, Mount Sinai School of Medicine, New York, NY 10029, USA
    Am Heart J 164:672-80. 2012
    ....
  59. pmc A fatty gut feeling
    Daniele Piomelli
    Department of Anatomy and Neurobiology, University of California, Irvine, CA 92612, USA
    Trends Endocrinol Metab 24:332-41. 2013
    ..OEA signaling may be a key component of the physiological system devoted to the monitoring of dietary fat intake, and its dysfunction might contribute to overweight and obesity. ..
  60. pmc The inhibition of fat cell proliferation by n-3 fatty acids in dietary obese mice
    Michal Hensler
    Department of Adipose Tissue Biology, Institute of Physiology Academy of Sciences of Czech Republic v v i, Prague, Czech Republic
    Lipids Health Dis 10:128. 2011
    ..The aim of this study was to further characterize the effects of LC n-3 PUFA on fat cell proliferation and differentiation in obese mice...
  61. ncbi Oleoylethanolamide exerts partial and dose-dependent neuroprotection of substantia nigra dopamine neurons
    B Galan-Rodriguez
    Departamento de Fisiologia Medica y Biofisica, Universidad de Sevilla, Av Sanchez Pizjuan 4, E 41009 Sevilla, Spain
    Neuropharmacology 56:653-64. 2009
    ..The occurrence of U-shaped dose-response relationships normally suggests toxicity due to high drug concentration or that opposing intracellular pathways are activated by different OEA doses...
  62. ncbi Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus
    Matthew A Cavender
    Department of Cardiovascular Medicine, The Cleveland Clinic, Cleveland, Ohio, USA
    Am J Cardiovasc Drugs 10:209-16. 2010
    ..If ongoing studies confirm the theoretical benefit and safety of dual PPAR-α/γ agonism, aleglitazar may become the first therapy demonstrated to reduce macrovascular complications in patients with diabetes...
  63. ncbi Regulation of Octn2 transporter (SLC22A5) by peroxisome proliferator activated receptor alpha
    Tomoji Maeda
    Department of Membrane Transport and Pharmacokinetics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba, Japan
    Biol Pharm Bull 31:1230-6. 2008
    ..In conclusion, our results indicate that the nuclear receptor PPARalpha directly up-regulates the expression of rOctn2 and increases the hepatic uptake of carnitine via rOctn2...
  64. pmc Reduction of body weight, liver steatosis and expression of stearoyl-CoA desaturase 1 by the isoflavone daidzein in diet-induced obesity
    A Crespillo
    Laboratorio de Medicina Regenerativa, Hospital Carlos Haya, Fundacion IMABIS, Pabellón de Gobierno, Malaga, Spain
    Br J Pharmacol 164:1899-915. 2011
    ..From this perspective, we have analysed the effects of daidzein, one of the main soy isoflavones, on diet-induced obesity in rats...
  65. ncbi Activation of peroxisome proliferator-activated receptor-α (PPARα) suppresses postprandial lipidemia through fatty acid oxidation in enterocytes
    Rino Kimura
    Laboratory of Molecular Function of Food, Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Uji, Kyoto 611 0011, Japan
    Biochem Biophys Res Commun 410:1-6. 2011
    ....
  66. ncbi Carnitine synthesis and uptake into cells are stimulated by fasting in pigs as a model of nonproliferating species
    Robert Ringseis
    Institute of Agricultural and Nutritional Sciences, Martin Luther University of Halle Wittenberg, Emil Abderhalden Strasse 26, D 06108 Halle Saale, Germany
    J Nutr Biochem 20:840-7. 2009
    ..It is concluded that nonproliferating species are also able to cover their increased demand for carnitine during fasting by an increased carnitine synthesis and uptake into cells...
  67. ncbi A Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio
    Shaohua Chen
    Zhejiang University, College of Medicine, The First Affiliated Hospital, Gastroenterology, Zhejiang, China
    J Gastroenterol Hepatol 23:1415-8. 2008
    ..This study analyzes the effect of the val227ala variant of the peroxisome proliferators-activated receptor-alpha (PPAR-alpha) on non-alcoholic fatty liver disease...
  68. ncbi Biological functions and metabolism of oleoylethanolamide
    Clementine Thabuis
    UMR1260 Nutriments Lipidiques et Prevention de Maladies Metaboliques, INRA, Marseille, 13385, France
    Lipids 43:887-94. 2008
    ..The investigation of the mechanism of action revealed that OEA activates PPAR-alpha and stimulates the vagal nerve through the capsaicin receptor TRPV1. Pre-clinical studies showed that OEA remains active when administered orally...
  69. pmc Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-alpha
    Xian sheng Huang
    Department of Cardiology, The Second Xiang Ya Hospital, Central South University, Changsha, Hunan, China
    Br J Pharmacol 158:706-12. 2009
    ..Apolipoprotein AV (apoAV) has been implicated in triglyceride metabolism. This study was designed to investigate the effect of the combination of statin and fibrate on apoAV and the underlying mechanism(s)...
  70. ncbi Activation of PPARalpha and PPARgamma reduces triacylglycerol synthesis in rat hepatoma cells by reduction of nuclear SREBP-1
    Bettina König
    Institute of Agricultural and Nutritional Sciences, Martin Luther University of Halle Wittenberg, Halle, Saale, Germany
    Eur J Pharmacol 605:23-30. 2009
    ..Thus, these data suggest that the triacylglycerol reducing effect of fibrates and thiazolidinediones is partially caused by inhibition of SREBP-1 activation via up-regulation of Insig...
  71. ncbi Opposing effects of adiponectin receptors 1 and 2 on energy metabolism
    Mikael Bjursell
    AstraZeneca R and D, Department of Integrative Pharmacology, SE 431 83 Molndal, Sweden
    Diabetes 56:583-93. 2007
    ..Thus, AdipoR1 and AdipoR2 are clearly involved in energy metabolism but have opposing effects...
  72. pmc Characterization of peroxisome proliferator-activated receptor alpha--independent effects of PPARalpha activators in the rodent liver: di-(2-ethylhexyl) phthalate also activates the constitutive-activated receptor
    Hongzu Ren
    National Health and Environmental Effects Research Lab Toxicogenomics Core, U S Environmental Protection Agency, Research Triangle Park, North Carolina 27711, USA
    Toxicol Sci 113:45-59. 2010
    ..Our results indicate that exposure to PPARalpha activators including DEHP leads to activation of multiple nuclear receptors in the rodent liver...
  73. ncbi Chronic treatment with the peroxisome proliferator-activated receptor alpha agonist Wy-14,643 attenuates myocardial respiratory capacity and contractile function
    Makhosazane Zungu
    Hatter Heart Research Institute, Department of Medicine, University of Cape Town Faculty of Health Sciences, Cape Town, South Africa
    Mol Cell Biochem 330:55-62. 2009
    ..This study demonstrates that chronic in vivo Wy-14,643 administration impaired cardiac contractile function in parallel with decreased mitochondrial respiratory function and increased uncoupling...
  74. pmc Leptin stimulates fatty acid oxidation and peroxisome proliferator-activated receptor alpha gene expression in mouse C2C12 myoblasts by changing the subcellular localization of the alpha2 form of AMP-activated protein kinase
    Atsushi Suzuki
    Division of Endocrinology and Metabolism, Department of Developmental Physiology, National Institute for Physiological Sciences, 38 Nishigonaka, Myodaiji, Okazaki, Aichi, Japan
    Mol Cell Biol 27:4317-27. 2007
    ..Our data thus suggest that the activation of and changes in the subcellular localization of alpha2AMPK are required for leptin-induced stimulation of fatty acid oxidation and PPARalpha gene expression in muscle cells...
  75. ncbi Effects of ovariectomy on PPAR alpha, SREBP-1c, and SCD-1 gene expression in the rat liver
    Amélie Paquette
    Département de Kinésiologie, Universite de Montreal, Montreal, Quebec, Canada
    Menopause 15:1169-75. 2008
    To investigate whether estrogen deficiency modifies the expression of important genes involved in hepatic lipid regulation, PPAR alpha, SREBP-1c, and SCD-1, in association with fat accumulation in the liver of ovariectomized rats.
  76. pmc PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition
    Dipak Panigrahy
    Vascular Biology Program, Children s Hospital, Department of Surgery, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 105:985-90. 2008
    ..Our results provide a mechanistic rationale for evaluating the clinical benefits of PPARalpha agonists in cancer treatment, alone and in combination with other therapies...
  77. ncbi "New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis
    Manu V Chakravarthy
    Endocrinology, Metabolism, and Lipid Research, Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Cell Metab 1:309-22. 2005
    ..These results suggest that products of the FAS reaction regulate glucose, lipid, and cholesterol metabolism by serving as endogenous activators of distinct physiological pools of PPARalpha in adult liver...
  78. ncbi Fenofibrate suppresses growth of the human hepatocellular carcinoma cell via PPARα-independent mechanisms
    Daisuke Yamasaki
    Graduate School of Pharmaceutical Sciences, Osaka University, 1 6 Yamadaoka, Suita, Osaka 565 0871, Japan
    Eur J Cell Biol 90:657-64. 2011
    ..Our data suggest that fenofibrate inhibits the proliferation of Huh7 cells by blocking Akt activation, and that CTMP is one of the key players for this antiproliferative property of fenofibrate in Huh7 cells...
  79. ncbi Dietary n-3 PUFA deprivation for 15 weeks upregulates elongase and desaturase expression in rat liver but not brain
    Miki Igarashi
    Brain Physiology and Metabolism Section, National Institute on Aging, NIH, Bethesda, MD 20892, USA
    J Lipid Res 48:2463-70. 2007
    ..These data suggest that liver n-3 PUFA metabolism determines DHA availability to the brain when DHA is absent from the diet...
  80. ncbi Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferator-activated receptor alpha transcription factor
    Hai lin Fang
    Institute of Environmental Health Sciences, Wayne State University, 2727 Second Ave, Room 4000, Detroit, MI 48201, USA
    Mol Pharmacol 67:1257-67. 2005
    ..Results also indicate that important species differences govern the transactivation of SULT2A gene transcription by nuclear receptors...
  81. ncbi Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice
    Kengo Tomita
    Department of Internal Medicine, Division of Gastroenterology and Hepatology, Keio University School of Medicine, Tokyo, Japan
    Hepatology 48:458-73. 2008
    ....
  82. ncbi Aldose reductase regulates hepatic peroxisome proliferator-activated receptor alpha phosphorylation and activity to impact lipid homeostasis
    Longxin Qiu
    Ministry of Education Key Laboratory for Cell Biology and Tumor Cell Engineering and Department of Biomedical Sciences, School of Life Sciences, Xiamen University, Xiamen 361005, China
    J Biol Chem 283:17175-83. 2008
    ..These data indicate that AR plays an important role in the regulation of hepatic PPARalpha phosphorylation and activity and lipid homeostasis. A significant portion of the AR-induced modulation is achieved through ERK1/2 signaling...
  83. pmc PPARγ-induced cardiolipotoxicity in mice is ameliorated by PPARα deficiency despite increases in fatty acid oxidation
    Ni Huiping Son
    Division of Preventive Medicine and Nutrition, Columbia University, New York, New York 10032, USA
    J Clin Invest 120:3443-54. 2010
    ....
  84. ncbi Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride
    Huating Li
    Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People s Hospital, Shanghai, China
    J Hepatol 53:934-40. 2010
    ..This study investigated the association of FGF21 with nonalcoholic fatty liver disease (NAFLD) in Chinese patients...
  85. ncbi Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease
    Leonie G Mikael
    Department of Human Genetics, Montreal Children s Hospital, Montreal, Canada
    Circ Res 98:564-71. 2006
    ..Transfection with a PPARalpha construct upregulated ApoA-I and MTHFR. Our results suggest that hyperhomocysteinemia may increase risk of atherosclerosis by decreasing expression of ApoA-I and increasing expression of CYP7A1...
  86. ncbi Mouse OCTN2 is directly regulated by peroxisome proliferator-activated receptor alpha (PPARalpha) via a PPRE located in the first intron
    Gaiping Wen
    Institute of Agricultural and Nutritional Sciences, Martin Luther Universitat Halle Wittenberg, Von Danckelmann Platz 2, 06120 Halle Saale, Germany
    Biochem Pharmacol 79:768-76. 2010
    ..In conclusion, the present study shows that mouse OCTN2 is a direct target gene of PPARalpha and that transcriptional upregulation of OCTN2 by PPARalpha is likely mediated via PPRE1 in its first intron...
  87. ncbi The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide
    Jesse Lo Verme
    Department of Pharmacology, 360 MSRII, University of California, Irvine, CA 92697 4625, USA
    Mol Pharmacol 67:15-9. 2005
    ..These findings indicate that PPAR-alpha mediates the anti-inflammatory effects of PEA and suggest that this fatty-acid ethanolamide may serve, like its analog OEA, as an endogenous ligand of PPAR-alpha...
  88. ncbi Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha
    Cheol Whee Park
    Division of Nephrology, Department of Internal Medicine, The Catholic University of Korea, 62, Yoido Dong, Youngdeungpo ku, Seoul, Korea 150 713
    Diabetes 55:885-93. 2006
    ..PPARalpha agonists may serve as useful therapeutic agents for type 1 diabetic nephropathy...
  89. ncbi Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons
    A Cimini
    Department of Basic and Applied Biology, University of L Aquila, via Vetoio n 10, 67010 Coppito AQ, Italy
    Neuroscience 130:325-37. 2005
    ..In particular, we point toward the PPARbeta/delta isotype as a key factor in neuronal differentiation...
  90. ncbi Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity
    Jonathan Buchanan
    Program in Human Molecular Biology and Genetics, University of Utah, Salt Lake City, 84112, USA
    Endocrinology 146:5341-9. 2005
    ....
  91. ncbi AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARalpha and PGC-1
    Woo Je Lee
    Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Republic of Korea
    Biochem Biophys Res Commun 340:291-5. 2006
    ..These data suggest that a novel transcriptional regulatory mechanism involving PPARalpha and PGC-1 exists that is responsible for long-term stimulation of fatty acid oxidation in skeletal muscle by AICAR...
  92. ncbi Resveratrol inhibits MMP-9 expression by up-regulating PPAR alpha expression in an oxygen glucose deprivation-exposed neuron model
    Gang Cheng
    Institute of Neurosurgery, Xijing Hospital, Fourth Military Medical University, 15 West Chang Le Road, Xi an, Shaanxi Province 710032, PR China
    Neurosci Lett 451:105-8. 2009
    ..The relationship between Res, MMP-9 and PPAR alpha or gamma was studied in an oxygen glucose deprivation-exposed neuron model...
  93. pmc Polyenephosphatidylcholine prevents alcoholic liver disease in PPARalpha-null mice through attenuation of increases in oxidative stress
    Wataru Okiyama
    Department of Metabolic Regulation, Institute on Aging and Adaptation, Shinshu University Graduate School of Medicine, Asahi 3 1 1, Matsumoto 390 8621, Japan
    J Hepatol 50:1236-46. 2009
    ..We aimed to explore the effects of PPC on ALD using ethanol-fed peroxisome proliferator-activated receptor alpha (Ppara)-null mice, showing several similarities to human ALD...
  94. ncbi Peroxisome proliferator-activated receptor-alpha contributes to the resolution of inflammation after renal ischemia/reperfusion injury
    Nimesh S A Patel
    Centre for Translational Medicine and Nephrology, William Harvey Research Institute, St Bartholomew s and the Royal London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, United Kingdom
    J Pharmacol Exp Ther 328:635-43. 2009
    ....
  95. ncbi The next generation of PPAR drugs: do we have the tools to find them?
    Barry G Shearer
    GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park, NC 27709, USA
    Biochim Biophys Acta 1771:1082-93. 2007
    ..In this review we will discuss the side effects associated the PPARs, how the current drugs in clinical development were discovered and new concepts in how to screen for PPAR drugs...
  96. ncbi MLDP, a novel PAT family protein localized to lipid droplets and enriched in the heart, is regulated by peroxisome proliferator-activated receptor alpha
    Tomohiro Yamaguchi
    Graduate School of Life Science, University of Hyogo, 3 2 1 Koto, Kamigori, Hyogo, 678 1297, Japan
    J Biol Chem 281:14232-40. 2006
    ..These results indicate that MLDP is a bona fide new PAT family member localized in LDs. Its expression depends on the physiological conditions and the action of PPARalpha...
  97. ncbi Peroxisome proliferator-activated receptor alpha (PPARalpha) potentiates, whereas PPARgamma attenuates, glucose-stimulated insulin secretion in pancreatic beta-cells
    Kim Ravnskjaer
    Department of Biochemistry and Molecular Biology University of Southern Denmark, Campusvej 55, 5230 Odense M, Denmark
    Endocrinology 146:3266-76. 2005
    ..These results show a strong subtype specificity of the two PPAR subtypes alpha and gamma on lipid partitioning and insulin secretion when systematically compared in a beta-cell context...
  98. pmc PPARalpha ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-kappaB and AP-1 pathways
    Sriram Ramanan
    Department of Cancer Biology, Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Free Radic Biol Med 45:1695-704. 2008
    ..Taken together, these data support the hypothesis that activation of PPARalpha can modulate the radiation-induced microglial proinflammatory response...
  99. ncbi Alcohol-induced steatosis in liver cells
    Terrence M Donohue
    Liver Study Unit, Research Service 151, VA Medical Center, 4101 Woolworth Ave, Omaha, NE 68105, USA
    World J Gastroenterol 13:4974-8. 2007
    ..Because steatosis is now regarded as a significant risk factor for advanced liver pathology, an understanding of the molecular mechanisms in its etiology is essential for development of effective therapies...
  100. pmc Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner
    Dipanjan Chanda
    Hormone Research Center, School of Biological Sciences and Technology, Chonnam National University, Gwangju, Republic of Korea
    Hepatology 50:880-92. 2009
    ..Fenofibrate exhibited a differential inhibitory pattern on PAI-1 gene expression depending on the transcription factors inhibited by SHP...
  101. ncbi Synthesis, biological evaluation and molecular modeling studies of arylidene-thiazolidinediones with potential hypoglycemic and hypolipidemic activities
    Lúcia Fernanda C da Costa Leite
    Departamento de Quimica, Universidade Católica de Pernambuco, Brazil
    Eur J Med Chem 42:1263-71. 2007
    ..Molecular modeling studies were carried out using the Autodock 3.0.5 and ADT 1.1 programs...

Research Grants63

  1. Xenobiotic sensors PXR and CAR and regulation of the UGT1 locus
    Robert H Tukey; Fiscal Year: 2012
    ..This application is the first attempt to investigate how human UGTs are regulated in mice, and to apply this animal to understand the impact of glucuronidation towards drug-drug interactions, drug metabolism and eventually disease. ..
  2. Sex differences in brain inflammation in experimental stroke
    Halina Offner; Fiscal Year: 2013
    ..Findings from this application could therefore lead to the development of new therapies for stroke such as PPAR[unreadable] agonists for females and MMP-9 antagonists for males. ..
  3. Effects of ethanol on lipid metabolism
    Min You; Fiscal Year: 2013
    ....
  4. Improved liver function and regeneration with A20
    Christiane Ferran; Fiscal Year: 2013
    ..Demonstrating A20's beneficial effects in our experimental models should set the basis for translating A20- based therapies into clinical practice. ..
  5. Diet-Induced Insulin Resistance and Myocardial Ischemia in Pigs
    Gregory G Schwartz; Fiscal Year: 2013
    ..Therefore, an additional goal is to determine whether chronic treatment with a PPAR alpha or gamma agonist modifies myocardial metabolic and contractile abnormalities in insulin resistant pigs...
  6. The Role of PPAR-alpha during Angiotensin II Hypertension
    Dexter L Lee; Fiscal Year: 2012
    ..End of Abstract) ..
  7. Perfluorooctane Sulfonate (PFOS) affects 1gM Production via IL-2
    Margie M Peden Adams; Fiscal Year: 2010
    ..Moreover, understanding the mode or mechanism of effect may also allow identification of markers that can be assessed in humans to better determine true risk as opposed to relative risk derived from rodent studies. ..
  8. Metabolism, Skeletal Muscle, Cardiac Disease, Exercise
    John P Konhilas; Fiscal Year: 2010
    ..This proposal will examine specific regulators of this disease process and evaluate their role during disease and exercise recovery. ..
  9. FABPs Mediate Activation of PPAR Alpha Receptors by N-Acylethanolamines
    Martin Kaczocha; Fiscal Year: 2012
    ..The overall outcome of this study will greatly enhance our understanding of NAE signaling and will ascribe novel functions to FABPs in endocannabinoid biology. ..
  10. Peroxisome Proliferator-Activated Receptor and Stroke
    Shobu Namura; Fiscal Year: 2013
    ..Obtained knowledge will increase our understanding about the importance of copper trafficking in cerebrovascular diseases. ..
  11. Stratum Corneum Acidification in the Neonate
    Kenneth Feingold; Fiscal Year: 2007
    ..these pathways develop, and the SC ultimately acidifies, a process that can be accelerated by activation of PPAR alpha, PPAR delta, and LXR...
  12. The function(s) and regulation of PPARs in the ovary
    Carolyn Komar; Fiscal Year: 2003
    Peroxisome proliferator-activated receptors (PPARs) are a nuclear receptor superfamily comprised of PPAR alpha, beta, and gamma...
  13. PEROXISOME PROLIFERATORS AND THE CELL CYCLE
    JANE ISHMAEL; Fiscal Year: 2002
    ..In general it is hoped that these studies will increase our understanding of the relationship between cell proliferation and hepatocarcinogenesis induced by nongenotoxic carcinogens. ..
  14. PEROXISOME PROLIFERATOR INDUCED HEPATOCARCINOGENESIS
    Sambasiva Rao; Fiscal Year: 2004
    ..abstract_text> ..
  15. PPAR Mediated Gene Expression in HIV Patients
    Marie Gelato; Fiscal Year: 2007
    ..Patients with HIV-LD have decreased expression of both PPAR gamma and PPAR alpha -regulated genes...
  16. DHEA:PPAR-Dependent and Independent Mechanisms of Action
    Russell Prough; Fiscal Year: 2006
    ..abstract_text> ..
  17. Perfluorooctane sulfonate (PFOS) Affects Immunity through PPAR-alpha.
    Margie Peden Adams; Fiscal Year: 2007
    ..of T-dependent antibody production by PFOS by assessing TNP-KLH antibody responses in wild type (control) and PPAR alpha null mice (129/SvlmJ &129S4/SvJae- Pparatm1Gonz/J mice; respectively). Mice will be treated with 0, 0...
  18. REGULATION OF HEPATITIS B VIRUS TRANSCRIPTION
    Alan McLachlan; Fiscal Year: 2003
    ..All of these studies are aimed at identifying possible targets for therapeutic intervention in chronic HBV infection. ..
  19. Prostaglandins: Kinins and Angiotensin Interactions
    JOHN MC GIFF; Fiscal Year: 2009
    ..3) Heme oxygenase activity and suppression of EET and 20-HETE synthesis. 4) Activation of peroxisome-proliferator-activated receptor alpha by Fibrates with stimulation of EET synthesis. ..
  20. MITOCHONDRIAL OXIDATIVE ENZYME EXPRESSION
    Tod Gulick; Fiscal Year: 2000
    ....
  21. NEW MOUSE MODELS OF DIABESITY
    Edward Leiter; Fiscal Year: 2002
    ..with a locus on Chromosome 15 tightly linked to the Peroxisome Proliferator-Activated Receptor alpha (PPAR alpha) gene...
  22. Lipid Kinetics During Acute Exercise in HIV
    William Cade; Fiscal Year: 2004
    ..Body composition will be examined using DEXA and 1H-MRI. Intra-myocellular and hepatic lipid content will be measured using 1H-MRS. ..
  23. Altered Lipid Metabolism & Age-Related Renal Dysfunction
    Moshe Levi; Fiscal Year: 2002
    ..abstract_text> ..
  24. PET DETECTION OF THE EFFECTS OF AGING ON THE HUMAN HEART
    ROBERT GROPLER; Fiscal Year: 2007
    ..The nitric oxide (NO) system and the peroxisome proliferator activated receptor alpha (PPAR alpha) are promising candidates that will be investigated...
  25. MINORITY PREDOCTORAL FELLOWSHIP PROGRAM
    COURTNEY WOODS; Fiscal Year: 2006
    ..The findings of this research will help in assessing human risk to these and perhaps other non-genotoxic carcinogens. ..
  26. 4-HNE and MDA adduction of SREBP-1 and PPAR-alpha in ALD
    Benjamin Stewart; Fiscal Year: 2007
    ..Ubiquitination and proteasomal degradation will be measured in a rabbit reticulocyte lysate (RRL) system. ..
  27. Novel PPAR alpha/gamma Agonist for Type 2 Diabetes
    EDWARD AMENTO; Fiscal Year: 2005
    ..Data from these studies will further characterize the potential of THR-0940 for treatment of type 2 diabetes and will provide valuable information to qualify this molecule for entry into clinical development. ..
  28. Vascular PPAR alpha and atherosclerosis
    Jayme Borensztajn; Fiscal Year: 2009
    ..In this application we propose to use mouse models of this disease to elucidate the mechanisms whereby certain drugs, by acting directly on blood vessels, can prevent the development, or cause the regression of atherosclerotic lesions. ..
  29. Calcineurin Signaling and Muscle Energy Metabolism
    Paul Schaeffer; Fiscal Year: 2003
    ..abstract_text> ..
  30. Profiles of Sucsceptibility to Toxicant Stress
    William Kaufmann; Fiscal Year: 2007
    ..The UNC-CH toxicogenomics research program has the scientific expertise and organizational infrastructure to provide significant and substantial benefits to the Toxicogenomics Research Consortium. ..
  31. 8 LOX AND SKIN CANCER SUSCEPTIBILITY
    Susan Fischer; Fiscal Year: 2004
    ..tumors? (4) Do 8-HETE or 9-HODE exert their effects by binding to and activating one or more of the PPAR isoforms in keratinocytes? Is the PPAR alpha isoform required for 8-HETE effects on differentiation and skin tumor susceptibility?
  32. Modulation of AhR-dependent signaling by PPARb/d
    Jeffrey M Peters; Fiscal Year: 2010
    ..abstract_text> ..
  33. Role of the PPARb in epithelial cell proliferation
    Jeffrey Peters; Fiscal Year: 2004
    ....
  34. Role of PPARbeta in colon carcinogenesis
    Jeffrey Peters; Fiscal Year: 2007
    ..abstract_text> ..
  35. IDENTIFICATION OF LIVER STEM CELLS IN PANCREAS
    Janardan Reddy; Fiscal Year: 2002
    ....
  36. Lipolytic Mechanisms of PPAR Activation
    Jorge Plutzky; Fiscal Year: 2007
    ..Through these programmatic efforts, insight will be gained into lipolysis as a mechanism for selective endogenous PPAR activation, and its distal transcriptional effects. ..
  37. FASEB Conference: Mechanisms of Liver Growth and Disease
    Janardan Reddy; Fiscal Year: 2002
    ..abstract_text> ..
  38. Biologic Studies with Peroxisome Proliferators and PPARs
    Janardan Reddy; Fiscal Year: 2008
    ..The studies we now propose will generate new information, which can provide insights into the molecular complexity and the functional implications of PPAR regulated gene expression in liver. ..
  39. BIOCHEMICAL CHARACTERIZATION OF PPAR
    JOHN VANDEN HEUVEL; Fiscal Year: 2008
    ..Taken together the proposed studies will greatly enhance our knowledge of PPARalpha's mechanism of action and hence our understanding of an important class of carcinogen. ..
  40. Transcriptional Coactivators in Liver Function
    Janardan Reddy; Fiscal Year: 2008
    ..These studies are expected to generate new information, with implications for human impact, which could provide novel avenues for developing strategies to regulate gene function by altering coactivator activity. ..
  41. Transcriptional Coactivators in Liver Function
    Janardan Reddy; Fiscal Year: 2007
    ..abstract_text> ..
  42. Endogenous Mechanisms of PPAR Modulation
    Jorge Plutzky; Fiscal Year: 2005
    ..Together, these studies integrate biochemical, biologic, and in vivo models to better understand how endogenous modulation of PPAR activity may determine biologic responses. ..
  43. ETHANOL METABOLISM IN PREGNANCY--ROLE OF DIET
    Martin Ronis; Fiscal Year: 2005
    ....
  44. BETA 1 AND BETA 3 ADRENORECEPTORS
    JAMES GRANNEMAN; Fiscal Year: 2001
    ..Aim 2. To further characterize the differential signaling properties of beta1- beta3-AR and to examine the cellular and molecular basis. Specific Aim 3. To examine the molecular pharmacology of beta3-AR-selective agonists. ..
  45. REGULATION OF LEUCINE OXIDATION
    Robert Harris; Fiscal Year: 2001
    ..To clone, express, and characterize BCKDH phosphatase and determine its role in regulation of the activity state of the BCKDH complex. ..
  46. CONTROL OF ENDOCANNABINOID RELEASE IN VIVO
    Daniele Piomelli; Fiscal Year: 2003
    ..Moreover, by uncovering the neurochemical interactions between cocaine and the endogenous cannabinoids, our studies will contribute to the general understanding of substance abuse and neuropsychiatric disorders. ..
  47. ETHANOL EFFECTS ON BONE FORMATION IN PREGNANCY
    Martin Ronis; Fiscal Year: 2006
    ..The role of CYP2E1 and free radicals in the skeletal toxicity of ethanol during these periods will also be studied. ..
  48. Mechanisms linking the adipogenic phenotype of aging muscle to insulin resistance
    Deborah M Muoio; Fiscal Year: 2010
    ....
  49. Ketone Dysregulation and Muscle Insulin Resistance
    DEBORAH MUOIO; Fiscal Year: 2006
    ..abstract_text> ..
  50. REGULATION OF EXPRESSION OF ALDH2
    David Crabb; Fiscal Year: 2003
    ..These studies should further our understanding of the tissue-specific control of ALDH2 and the potential that dietary factors have on its expression. ..
  51. REGULATION OF PYRUVATE DEHYDROGENASE KINASE
    Robert Harris; Fiscal Year: 2008
    ....
  52. Oleylethanolamide derivatives as anti-obesity agents
    Daniele Piomelli; Fiscal Year: 2005
    ....
  53. Adiponectin Improves Vascular Function In High Glucose
    Kevin Williams; Fiscal Year: 2007
    ..abstract_text> ..
  54. Effects of ethanol on AMP kinase signaling
    David Crabb; Fiscal Year: 2008
    ..It may also shed light on the pathogenesis of non-alcoholic fatty liver disease. [unreadable] [unreadable] [unreadable]..
  55. Role of Endocannabinoids in the Behavioral Consequences of Social Isolation
    Daniele Piomelli; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  56. Adiponectin: Vascular Responses and Signaling Mechanisms
    Kevin Williams; Fiscal Year: 2007
    ....
  57. ETHANOL, INSULIN/IGF SIGNALING AND NEURONAL MIGRATION
    Suzanne de la Monte; Fiscal Year: 2008
    ..abstract_text> ..
  58. Role of oleoylethanolamide in the control of food intake
    Daniele Piomelli; Fiscal Year: 2010
    ....
  59. Cerebral Microvascular Endothelin Production
    Momoh Yakubu; Fiscal Year: 2003
    ..Our understanding of the mechanisms underlying the consequences of SAH will make it possible for early and appropriate intervention to prevent or reduce these complications from hemorrhagic stroke. ..
  60. TYROSINE PHOSPHATASES IN HUMAN OBESITY AND DIABETES
    Barry Goldstein; Fiscal Year: 2001
    ....